Filing summary
Entity and period: The supplied filing is Mind Medicine (MindMed) Inc.’s Form 10-K for the fiscal year ended December 31, 2021, filed March 28, 2022. This does not match the request metadata identifying Definium Therapeutics, Inc. The filing reports annual results, not a standalone 2021 fourth quarter. Amounts below are U.S. dollars.
Business context and reporting period
MindMed is a clinical-stage biopharmaceutical company developing treatments for brain health disorders, including psychiatry, addiction, pain and neurology. It had no approved products and had not generated revenue. Its principal candidates were MM-120 (lysergide/LSD), MM-110 (zolunicant, derived from 18-MC) and MM-402 (R(-)-MDMA). In February 2021, it acquired HealthMode, a digital medicine and clinical-measurement technology company.
Financial performance and position
| Metric | FY 2021 | FY 2020 |
|---|---|---|
| Revenue | None generated | None generated |
| Research and development expense | $34.8 million | $18.6 million |
| General and administrative expense | $59.1 million | $14.4 million |
| Total operating expenses / operating loss | $93.9 million | $33.0 million |
| Net loss | $93.0 million | $33.9 million |
| Basic and diluted loss per share | $0.23 | $0.13 |
| Operating cash used | $45.8 million | $23.6 million |
| Cash at year-end | $133.5 million | $80.1 million |
At December 31, 2021, current assets were $137.2 million, current liabilities $10.4 million, total liabilities $12.3 million and shareholders’ equity $151.7 million. The balance sheet shows no conventional borrowings. Working capital was reported as $127.5 million. No operating margin is meaningful because the company had no revenue.
Financing activities provided $98.8 million in cash during 2021, including $81.9 million net proceeds from share and warrant issuances, $11.2 million from warrant exercises and $5.7 million from option exercises. The company reported an accumulated deficit of $137.7 million.
Material changes versus the prior year
- Net loss increased by $59.1 million, or 174%, while operating expenses rose 184%.
- R&D expense increased 87%, reflecting higher MM-120, MM-110 and other program costs, partly offset by lower external collaboration expense.
- G&A expense rose substantially, mainly due to stock-based compensation. Total stock-based compensation was $42.7 million in 2021 versus $7.4 million in 2020; $21.9 million of 2021 G&A stock compensation related to award modifications.
- Cash increased by $53.4 million, principally because financing inflows exceeded operating cash use.
- The HealthMode acquisition added $19.9 million of goodwill and $9.5 million of developed technology, with the technology amortized over three years.
Outlook, risks and unusual items
- Management expected existing cash to fund its current operating plan into 2024, while cautioning that actual spending and development timelines could differ. The company expected to need substantial additional capital over time; no committed external funding source was disclosed.
- Planned development included MM-120 Phase 2 studies for anxiety and ADHD and a chronic-pain study expected to begin in late 2022; a Phase 2a MM-110 opioid-withdrawal trial in 2022; and a Phase 1 MM-402 study expected in 2023. The filing describes MM-120’s GAD stage inconsistently in different sections, including Phase 2 and Phase 2b.
- Key risks include clinical-trial failure or delay, regulatory approval uncertainty, the need for controlled-substance scheduling, patient and clinician acceptance, reimbursement, competition, and dependence on external research, trial and manufacturing partners. The company said it lacked long-term or redundant supply arrangements for its candidates.
- Management reported no significant COVID-19 disruption to date but warned that the pandemic could affect trial timelines, logistics and funding access.
- Known research and development and other contractual commitments were approximately $29.3 million at year-end, most cancellable with notice. Some agreements may also require future milestone or royalty payments; timing and amounts are uncertain. The filing reports no material pending litigation.
- A material weakness in internal control over financial reporting was identified: the company did not accrue a $3.2 million liability when it committed in 2020 to a $5.0 million research-program pledge payable over five years. Management said it took steps to improve controls. The auditor gave an unqualified opinion on the financial statements, but did not audit or opine on internal control effectiveness.
Important facts for investors to verify
- Confirm the issuer identity: the filing is for Mind Medicine (MindMed) Inc., not Definium Therapeutics, Inc.
- Review subsequent cash burn, financing and dilution against management’s stated runway into 2024.
- Check trial progress, results and updated timelines for MM-120, MM-110 and MM-402, including clarification of MM-120’s reported GAD phase.
- Assess remediation and any later disclosures concerning the material weakness and the research pledge accrual.
- Review controlled-substance scheduling requirements, clinical supply arrangements, and the status of the $29.3 million commitments.